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Summary The effect of low (0.08,uUg-' body wtmin-1) and high (0.16YuUg-' body wtmin-') rates of
vasopressin infusion on blood flow to normal liver tissue and to liver metastases derived from azoxymethane
induced colorectal carcinomas was studied in 36 male Wistar rats. Portal venous flow was measured by
electromagnetic flowmetry and blood flow to normal and metastatic liver tissue by the clearance of xenon-133
injected directly into the liver parenchyma or metastasis. The low rate of vasopressin infusion decreased portal
venous flow but increased blood flow to normal and metastatic liver tissue while at the higher rate of infusion
these effects were reversed. Hepatic artery ligation (HAL) immediately following a low rate of vasopressin
infusion abolished the observed increase in blood flow to both normal liver tissue and metastases. HAL
immediately following the higher rate of vasopressin infusion further reduced blood flow to metastases but did
not further alter blood flow to normal liver tissue. HAL prior to the infusion of the vasoactive drug
significantly reduced blood flow to metastatic liver tissue, increased portal venous flow and was without effect
on blood flow to normal liver tissue. Following HAL, blood flow to metastatic liver tissue was not further
altered by either the low or high rates of vasopressin infusion. However, blood flow to normal liver tissue after
HAL was reduced by a low rate of infusion of vasopressin and increased by the higher rate of infusion. The
results of this study indicate that blood flow to normal or metastatic liver tissue can be increased or decreased
by differential rates of infusion of vasopressin. These observations may have important implications in the
treatment of liver metastases in man where different rates of vasopressin infusion may potentiate the effects of
hepatic artery ligation or cytotoxic therapy.
Hepatic metastases are present in approximately
20% of patients with colorectal carcinoma at initial
presentation (Bengmark & Hafstrom, 1969; Oxley
& Ellis, 1969; Neilson et al., 1973). The prognosis
of these patients is poor, the median survival being
reported to be from 3-9 months (Oxley & Ellis,
1969; Nelson et al., 1973). There is therefore, a
great need for more satisfactory management to
improve outlook and prolong survival.
Metastases in the liver obtain the majority, if not
all their blood supply from the hepatic artery
(Breedis & Young, 1954; Ackerman et al., 1969).
Therefore hepatic metastases have been treated by
delivery of a chemotherapeutic agent via the hepatic
artery (Mattson et al., 1980; Reed et al., 1980).
Although several reports have suggested a higher
rate of palliation with the intra-arterial infusion of
chemotherapeutic agents compared to systemic
chemotherapy, a recent prospective study has failed
to substantiate these claims (Grage et al., 1979).
The dependence of liver metastases on the hepatic
artery has also led to attempts to treat non-
resectable cases either by ligation or embolisation,
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followed by chemotherapy (Namamura et al.,
1981). However, these procedures have proved to
be disappointing in improving long-term symptom-
free survival.
Vasopressin has been used for several years for
the initial treatment of bleeding oesophageal varices
(Kehne et al., 1956; Shields, 1977). The aim of the
treatment is to reduce portal pressure while
maintaining perfusion of the liver. The reduction in
portal pressure following the infusion of
vasopressin is achieved through splanchnic
vasoconstriction, while adequate liver perfusion
appears to result from increased hepatic artery
flow. However, clinical and experimental studies
have shown that the rate of vasopressin infusion
required to elicit such a favourable haemodynamic
response is critical, higher doses being ineffectual or
even deleterious (Chojkier et al., 1979; Mooney et
al., 1980). Alteration of the relative proportions of
portal venous flow and hepatic artery flow by a
vasoactive drug such as vasopressin may assure a
preferential delivery of cytotoxic agents to hepatic
tumours. In addition, a profound intrahepatic
vasoconstrictor effect may enhance the beneficial
action of hepatic artery ligation or embolisation.
This study was undertaken to investigate the
effects of ligation of the hepatic artery and of
vasopressin, singly or in combination, upon the
blood supply to normal liver and to hepatic
metastases.
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Materials and methods
One hundred and eighty male Wistar rats (250g)
received s.c. injections of azoxymethane (10mgkg-1
body wt week-1) for 12 weeks. Forty-four weeks
following the end of the azoxymethane treatment
the animals were anaesthetised by an i.p. injection
of sodium pentobarbitone and subjected to
laparotomy. Multiple colonic tumours were found
in all animals but liver metastases were only
observed in 47. Only rats with metastases in the
liver were used in this study.
Two studies were carried out differing from each
other in the timing of hepatic artery ligation. In the
first study, hepatic artery ligation was carried out
after the infusion of vasopressin while in the second
experiment the artery was ligated before the
infusion of the hormone.
Study 1: The effect on portal haemodynamics of
vasopressin infusion followed by hepatic artery
ligation
Vasopressin was administered at two rates of
infusion, 0.08 and 0.16jUg- 1 body wtmin- 1 to
two groups of 6 rats. These rates of vasopressin
infusion were selected on the basis of previous
observations in the "normal" rat (Mooney et al.,
1980). The hormone was infused via a cannula
placed in the femoral vein for 20min, the total
volume of infusate being 0.2ml. A control group of
6 azoxymethane treated rats received a 20min
infusion of the same volume of isotonic saline.
Arterial blood pressure was recorded
continuously by means of a pressure transducer
(Bell & Howell) connected to a cannula placed in
the femoral artery. An electromagnetic flow prope
of appropriate size was placed around the mobilised
portal vein. The probe was connected to a
Biotronix Flowmeter (Model BL 613 EZ-AZ) and
the portal flow (in mlmin-1) was recorded
continuously throughout the experiment.
Liver blood flow to normal and metastatic liver
tissue was measured by the clearance of 133Xe
(Lewis, 1970; Gelin et al., 1968; Taylor et al., 1979).
A small volume (2,l) of 133Xe was injected into the
liver substance or a hepatic metastasis using a fine
needle, which was held in place for several seconds
to prevent leakage along the needle track. The
clearance of 133Xe from the liver was measured by
external scanning using a collimated sodium-iodide
scintillation counter attached to a pen recorder.
Since in the rat, the clearance of 133Xe following
parenchymal injection follows a monoexponential
curve, liver blood flow was calculated from the
formula K100, where K is the exponential rate
constant (and is equal to 0.693/t2, where t- is the
time taken for hepatic activity to fall to half its
initial value) and A is the partition coefficient of
liver tissue (McKenzie et al., 1976; Conn, 1961).
Liver blood flow to metastatic tissue was calculated
using the same formula as that used for normal
tissue, the partition coefficient for metastatic tissue
being the same as normal liver tissue (Mooney,
1981).
Liver blood to flow to normal and metastatic
tissue was measured before and after the infusion of
vasopressin. Immediately following the infusion of
vasopressin the hepatic artery was ligated and the
haemodynamic measurements were repeated.
Study 2: The effect of vasopressin on hepatic
haemodynamics following hepatic artery ligation
The experimental set-up was essentially the same as
in the first study, except that the hepatic artery was
ligated after basal measurements of portal venous
flow, liver blood flow and arterial blood pressure.
The haemodynamic measurements were repeated
immediately after and 10min following hepatic
artery ligation. Vasopressin was then infused at
either 0.08 or 0.l6piUg-1 body wtmin-1 to two
groups of 6 rats for 20min, the total volume of
infusate being 0.2ml. A control group of
azoxymethane treated rats received a similar
infusion of isotonic saline. Arterial pressure and
portal venous flow were again recorded
continuously throughout the experiment and
measurements of blood flow to normal and
metastatic tissue repeated at the end of the infusion.
Statistical analysis
The statistical significance of any differences in
hepatic haemodynamics were evaluated using
Student's t-test for paired and unpaired data.
Results
Histology
The livers of all animals treated with azoxymethane
showed some evidence of liver damage, notably
hepatocyte swelling and some necrosis. However,
cirrhosis was not present nor were there any foci of
microcancer.
Study 1: The effect on portal haemodynamics of
vasopressin infusion followed by hepatic artery
ligation.
Arterial bloodpressure
The infusion of vasopressin resulted in an
immediate fall in arterial blood pressure, followedVASOPRESSIN AND BLOOD FLOW TO LIVER METASTASES 787
within 30 sec by a sharp and significant increase
which was maintained for the duration of the
infusion. The increase in arterial blood pressure
following the infusion of 0.08 or 0.16 pUg-' body
wtmin ' of vasopressin was similar (mean increase
48.7 +5.6 and 51.3 +6.2mmHg respectively). The
infusion of saline did not affect arterial blood
pressure. Arterial blood pressure was not
significantly changed by hepatic artery ligation
following the infusion of either vasopressin or
saline.
Portal venousflow (Table I)
Before infusion, portal venous flows in the 3 groups
of rats were similar. Following infusion of
0.08 pUg-1 body wtmin- 1 vasopressin there was a
significant reduction (39%) in portal venous flow
below the preinfusion levels (P<0.01). However,
following infusion of 0.16pU g-1 body wtmin- 1
vasopressin, portal venous flow increased (38%)
(P<0.01). Saline infusion did not alter portal
venous flow. The changes in portal venous flow
following vasopressin infusion at either rate was not
altered by hepatic artery ligation. However,
following the infusion of saline, hepatic artery
ligation resulted in an increase in portal venous
flow.
Liver bloodflow (Table II)
The blood flow in hepatic metastases was
significantly less than that in normal liver tissue in
all 3 groups of rats, before the infusion of
vasopressin. With an infusion of 0.08 [LUg-1 body
wtmin-1, hepatic blood flow significantly increased
in both normal and metastatic liver tissue.
Conversely, blood flow to both normal and
metastatic liver tissue was significantly reduced
following an infusion of 0.16jUg- 1 body wtmin- 1,
vasopressin. Saline had no effect on liver blood flow
to either normal or metastatic liver tissue.
Hepatic artery ligation abolished the increase in
blood flow to both normal and metastatic liver
tissue that was observed following the infusion of
0.08 Ug- 1 body wtmin- 1 vasopressin. The
decrease in blood flow to metastatic tissue following
hepatic artery ligation was significantly greater than
Table I The effect of portal venous flow of vasopressin infusion
followed by hepatic artery ligation.
Portal venousflow (ml 1min)
(Mean +s.e.)
Rate ofinfusion End of
ofvasopressin vasopressin Post-hepatic
(pUg-I body wtmin-1) Basal infusion artery ligation
0.08 28.3 +2.6 16.5+2.3a 17.5 +2.2
0.16 30.7+3.6 42.6+4.2a 43.7 +3.3
Saline 29.5 +4.7 28.1+3.6 37.5+3.la
The results are expressed as Mean+s.e.
'Denotes a significant difference from the basal levels (P<0.05).
Table II The effect on blood flow to normal and metastatic liver tissue of vasopressin infusion followed by hepatic
artery ligation.
Bloodflow (mlmin- 1 OOg-1)
Normal liver tissue Metastases
Rate ofinfusion End of End of
of vasopressin vasopressin Post-hepatic vasopressin Post-hepatic (pUg-1 body wtmin-1) Basal infusion artery ligation Basal infusion artery ligation
0.08 48.3 +3.8 61.9 +4.9a 44.6+5.0' 28.2+3.6 43.5+2.9a 9.4+ 1.5a
0.16 52.8+3.7 38.0+4.6a 37.7+4.6 30.7+3.2 18.9+ 1.38 7.6+0.8a
Saline 44.8 +4.9 45.8+4.4 57.5+5.6a 26.9+4.1 27.7+3.8 8.5+2.2a
The results are expressed as Mean +s.e.
aDenotes a significant differences from the basal levels (P<0.05).788 S.A. JENKINS et al.
that observed in normal tissue. Hepatic artery
ligation following an infusion of either 0.16yUg-1
body wtmin-1 vasopressin or saline significantly
reduced blood flow to metastatic tissue but not to
normal liver tissue.
Study 2: The effect of vasopressin on hepatic
haemodynamics following hepatic artery ligation
Arterial blood pressure
Arterial blood pressure was not significantly
changed immediately after or 10min following
hepatic artery ligation. The infusion of vasopressin
at a rate of 0.08 or 0.16yUg-1 body wtmin-1
vasopressin increased arterial blood pressure by
approximately the same magnitude (53.1+7.3 and
55.9+6.1mmHg respectively). Saline was without
effect on arterial blood pressure.
Portal venousflow (Table III)
Portal venous flow was significantly increased
10min following hepatic artery ligation in all 3
groups of rats. Ten minutes following hepatic artery
ligation, an infusion of 0.08/iUg-g1 body wtmin-'
vasopressin, significantly decreased portal venous
flow. Conversely, an infusion of 0.16MUg-' body
wtmin-m vasopressin, significantly increased portal
venous flow. An infusion of saline had no effect on
portal flow following hepatic artery ligation.
Liver bloodflow (Table IV)
Hepatic artery ligation had no significant effect on
blood flow to normal liver tissue in any of the 3
groups of rats studied. Blood flow to metastatic
tissue was however, significantly reduced by hepatic
artery ligation in all 3 groups of animals. Ten
minutes following hepatic artery ligation an infusion
of 0.08pUg-' body wtmin 1 vasopressin
significantly reduced blood flow to normal liver
tissue but was without significant effect on blood
flow to metastatic tissue. An infusion of 0.16yUg-1
body wtmin-1 vasopressin following hepatic artery
ligation increased blood flow to normal tissue but
was without effect on the blood flow to metastases.
Saline had no effect on blood flow to normal or
metastatic liver tissue.
Table III The effect of vasopressin on portal venous flow following
hepatic artery ligation.
Portal venousflow (mlmin-1)
Rate ofinfusion 10min after End of
ofvasopressin hepatic artery vasopressin
(uUg body wtmin 1) Basal ligation infusion
0.08 28.7+2.7 37.2+2.2a 22.8+ 1.9a
0.16 27.1+2.4 39.3+2.1l 47.7+2.6a
Saline 25.8+2.9 37.5+3.2a 38.2+2.5
The results are expressed as Mean+s.e.
aDenotes a significant difference from the balsal levels (P<0.05).
Table IV The effect of vasopressin on blood flow to normal and metastatic liver tissue following hepatic
artery ligation.
Bloodflow (mlmin- lJOOg-1)
Normal liver tissue Metastases
Rate ofinfusion 10min 10min End of
ofvasopressin after End of after vasopressin
(pUg1 body wtmin ') Basal ligation infusion Basal ligation infusion
0.08 45.9+2.3 45.2+2.2 17.6+2.Oa 25.0+2.2 8.1 +0.9a 7.5+0.7
0.16 44.4+2.9 44.9+3.3 57.5+3.8a 27.3+4.1 8.3+1.2a 8.6+0.9
Saline 42.3 +3.9 41.9+3.6 43.1+2.6 24.6+1.8 8.8+1.5a 8.1+ 1.0
The results are expressed as Mean+s.e.
aDenotes a significant difference from the basal levels (P<0.05).VASOPRESSIN AND BLOOD FLOW TO LIVER METASTASES 789
Discussion
All rats treated with azoxymethane developed some
hepatocellular damage but there was no histological
evidence of either cirrhosis or foci of microcancer.
Furthermore, liver blood flow measured by the
clearance of xenon-133 is lower in azoxymethane
treated rats than in untreated rats (Mooney &
Taylor, 1981). However, hepatic artery ligation has
no effect on blood flow to the liver of
azoxymethane treated rats (Mooney & Taylor,
1981). Therefore, in this study non-metastatic tissue
is referred to as "normal", although we accept that
there is some hepatocellular damage and
impairment of blood flow.
The results of this study clearly indicate that the
effects of vasopressin on portal venous flow and
blood flow to normal and metastatic tissue are
dependent on the rate of its infusion. The response
is biphasic, and accords with previous observations
(Mooney et al., 1980). Thus at the lower rate of
vasopressin infusion (0.08,Ug-' body wtmin-1)
portal venous flow was decreased but total blood
flow to normal and metastatic liver tissue was
increased; at a higher rate of infusion (0.16pUg'1
body wtmin-1) these effects were reversed. These
contrasting responses were consistently observed
(Figure 1).
The precise mechanism whereby vasopressin
brings about the observed changes in portal venous
flow is not clear. The most generally accepted
explanation is that the fall in portal venous flow
following vasopressin infusion is the result of
constriction of the splanchnic arterioles (Schwartz,
1970), although a direct effect on the intraheptic
portal resistance sites has also been suggested
(Richardson & Withrington, 1981). In the present
study, an infusion of vasopressin resulted in a
marked increase in arterial blood pressure,
suggesting that splanchnic vasoconstricution was, at
least in part, responsible for the observed decrease
in portal venous flow. However, it seems unlikely
that the increase in portal venous flow following the
infusion of 0.16MuUg-1 body wtmin-1 can be
explained in terms of changes in splanchnic
vasoconstriction since aterial blood pressure was
also markedly elevated at this rate of infusion.
Possibly, this phenomenon may be caused by a
change in the intrahepatic vascular resistances
mediated directly or indirectly by high rates of
infusion of vasopressin.
Blood flow to normal and metastatic tissue was
significantly increased following an infusion of
0.08,uUg- 1 body wtmin- ' of vasopressin. Since the
blood supply of the liver is derived from the hepatic
artery and portal vein and because an infusion of
0.08yuUg` body wtmin-1 of vasopressin reduced
portal venous flow, the increase in blood flow to
both normal and metastatic tissue is probably
effected by an increase in hepatic artery flow. This
suggestion is supported in the present study by the
observation that hepatic artery ligation abolished
the increase in blood flow to both normal and
metastatic liver tissue following vasopressin infusion
while ligation prior to the infusion prevented the
increase.
The precise mechanism whereby vasopressin
elicits an increased flow in the hepatic artery is not
clear. Conn (1973) has suggested that the increase
in hepatic artery flow following vasopressin infusion
is secondary to a reduction in portal flow. However,
the hepatic artery-response to vasopressin is much
greater when the hormone is administered intra-
arterially than intravenously suggesting a direct
effect on the artery (Richardson & Withrington,
1975). Nevertheless, the "dilator" effect of
vasopressin on the hepatic arterial bed may be
indirect and reflect passive dilation of the pre-
arteriolar vessels due to increases in systemic blood
pressure (Richardson & Withrington, 1981).
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The reduction in blood flow to normal and
metastatic liver tissue following a higher rate of
vasopressin infusion (0.16yUg1 body wtmin-')
would again seem to reflect an alteration in hepatic
artery flow, since portal venous flow at this rate of
infusion was increased. This suggestion is supported
by the observation that hepatic artery ligation
significantly reduced blood flow to metastatic tissue
whose blood supply is derived predominantly from
the hepatic artery. Conversely hepatic artery
ligation had little effect on blood flow to "normal"
liver tissue which receives a blood supply from both
the hepatic artery and portal vein, portal venous
flow being increased following an infusion of
0.16,1Ug-' body wtmin-m vasopressin. Further-
more, ligation of the hepatic artery prior to the
infusion of 0.16pUg` body wtmin- vasopressin,
abolished the reduction in blood supply to liver
metastases when the hormone was infused at this
higher rate without prior ligation. Vasopressin has
been reported to elicit hepatic artery
vasoconstriction in the dog (Richardson &
Withrington, 1975). Possibly, therefore, at a rate of
infusion of 0.16,uUg1 body wtmin- 1 the hepatic
artery cannot escape the generalised vasoconstrictor
properties of the hormone, and this results in a
decreased flow through the hepatic artery and an
overall decrease in liver blood flow.
The observations of this study on the effects of
different rates of infusion of vasopressin on hepatic
haemodynamics may have important practical
implications in the management of patients
presenting with liver metastases. Firstly, vasopressin
infusion at a rate comparable to that currently used
for the management of bleeding oesophageal
varices, may, by reducing portal venous flow,
potentiate the effects of hepatic artery ligation or
embolisation in rendering tumour tissue ischaemic.
Secondly, since this rate of vasopressin infusion
increases hepatic artery flow, the simultaneous
administration of vasopressin and a cytotoxic agent
may ensure a preferential delivery of the latter to
liver metastases. Lastly, a higher rate of infusion of
vasopressin that is currently used for the emergency
control of bleeding oesophageal varices, by
increasing portal venous flow, may potentiate
cytotoxic therapy given via the portal vein in
combination with hepatic artery ligation or
embolisation.
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